Strategic Drug Solutions

Strategic Drug Solutions (SDS) is a specialty pharmaceutical company and drug development consultancy based in San Diego, California. The company focuses on the development of proprietary, value-added products using the 505(b)(2) regulatory pathway, particularly in the areas of central nervous system (CNS) disorders and pain management. SDS is known for its lead candidate, SDS-101, a proprietary sublingual formulation of ketamine designed for the treatment of treatment-resistant depression (TRD). In addition to its internal pipeline, the company provides strategic and tactical drug development services to other biotech and pharmaceutical firms. The firm's leadership team possesses extensive experience in clinical development, regulatory affairs, and commercial strategy.